Drug Profile
CNJ I02
Latest Information Update: 22 May 2002
Price :
$50
*
At a glance
- Originator Cangene Corporation
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 22 May 2002 Discontinued - Preclinical for HIV infections treatment in Canada (unspecified route)
- 18 May 2001 No-Development-Reported for HIV infections treatment in Canada (Unknown route)
- 18 Dec 1998 New profile